In a landmark decision that will reshape how we approach obesity treatment worldwide, the World Health Organization1 has released its first-ever clinical guidelines recommending GLP-1 therapies for adults living with obesity. This isn’t merely another drug approval or incremental policy update; it represents a transformation in how the world’s leading health authority understands and addresses a condition affecting over 1 billion people globally.